Arbutus Biopharma Files Definitive Proxy Statement

Ticker: ABUS · Form: DEF 14A · Filed: Apr 4, 2025 · CIK: 1447028

Arbutus Biopharma Corp DEF 14A Filing Summary
FieldDetail
CompanyArbutus Biopharma Corp (ABUS)
Form TypeDEF 14A
Filed DateApr 4, 2025
Risk Levellow
Sentimentneutral

Sentiment: neutral

Topics: proxy-statement, annual-meeting, governance

Related Tickers: ABUS

TL;DR

Arbutus Biopharma (ABUS) filed its proxy statement for the May 21st meeting. Vote your shares!

AI Summary

Arbutus Biopharma Corp filed a Definitive Proxy Statement (DEF 14A) on April 4, 2025, for its annual meeting on May 21, 2025. The filing concerns the solicitation of proxies from shareholders regarding matters to be voted on at the meeting. Arbutus Biopharma, previously known as Tekmira Pharmaceuticals Corp, is in the pharmaceutical preparations industry.

Why It Matters

This filing provides shareholders with crucial information about the upcoming annual meeting, including proposals to be voted on, which can impact the company's governance and strategic direction.

Risk Assessment

Risk Level: low — This is a routine proxy filing for an annual meeting and does not contain new material financial or operational information that would inherently increase risk.

Key Numbers

  • DEF 14A — Filing Type (Definitive Proxy Statement filed with the SEC.)

Key Players & Entities

  • Arbutus Biopharma Corp (company) — Registrant
  • Tekmira Pharmaceuticals Corp (company) — Former Company Name
  • 20250404 (date) — Filing Date
  • 20250521 (date) — Meeting Date

FAQ

What is the purpose of this DEF 14A filing?

The purpose of this DEF 14A filing is to provide shareholders with information and solicit their proxies for the upcoming annual meeting of shareholders scheduled for May 21, 2025.

When was this proxy statement filed with the SEC?

This proxy statement was filed with the SEC on April 4, 2025.

What is the company's Central Index Key (CIK)?

The company's Central Index Key (CIK) is 0001447028.

What was Arbutus Biopharma's former name?

Arbutus Biopharma Corporation was formerly known as Tekmira Pharmaceuticals Corp.

What is the company's primary business classification?

The company is classified under the Standard Industrial Classification code 2834, which pertains to Pharmaceutical Preparations.

Filing Details

This Form DEF 14A (Form DEF 14A) was filed with the SEC on April 4, 2025 regarding Arbutus Biopharma Corp (ABUS).

View full filing on EDGAR

View Full Filing

View this DEF 14A filing on SEC EDGAR

View on ReadTheFiling | About | Contact | Privacy | Terms

Data from SEC EDGAR. Not affiliated with the SEC. Not investment advice. © 2026 OpenDataHQ.